Assessing Jazz Pharmaceuticals: Insights From 12 Financial Analysts
Portfolio Pulse from Benzinga Insights
Jazz Pharmaceuticals (NASDAQ:JAZZ) has been analyzed by 12 financial analysts, showing a range of opinions from bullish to bearish. The average 12-month price target is $169.25, a decrease from the previous $173.33. Analysts have adjusted their ratings and price targets, reflecting their views on the company's performance. Jazz Pharmaceuticals has shown a positive revenue trend with a 6.95% growth rate, strong net margin, and effective asset utilization, but faces challenges with below-average ROE.
October 04, 2024 | 5:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Jazz Pharmaceuticals has received mixed analyst ratings, with a current average price target of $169.25, down from $173.33. The company shows positive revenue growth and strong net margin but faces challenges with ROE.
The mixed analyst ratings and slight decrease in the average price target suggest a neutral short-term impact on JAZZ's stock price. The company's positive revenue growth and strong net margin are offset by challenges in ROE, leading to a balanced outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100